Immix Biopharma is trading 5.2% lower at $11.30, with the decline appearing mainly linked to biotech and broader-market weakness amid elevated Treasury yields and crude above $100.
- The move continues the September 23 decline, when shares fell 7.09%.
- No fresh company-specific announcement or catalyst was identified in available coverage. The latest company news concerned its September 14–16 Morgan Stanley conference participation.